Latest news

Debiopharm Group™ initiates phase I dose escalation study with Debio 1347 (CH5183284) in advanced solid tumors with FGFR alterations

Debiopharm Group™ presents the ‘Debiopharm Group Life Sciences Award 2013’ and two ‘Junior Debiopharm Group Life Sciences Awards 2013’ during…

Alacrita and Debiopharm Group™ collaborate to identify early stage drug candidates from the Massachusetts life science cluster

Quartz Bio SA supports Debiopharm Group™ precision medicine bioinformatics

Aurigene and Debiopharm Group™ report nomination of development candidate Debio 0617B in oncology

Diagnoplex S.A. closes a financing round led by Debiopharm Group™

Debiopharm Group™ announces additional phase I clinical trial evaluating Debio 1143 combined with chemotherapies for patients with selected solid malignancies

Financement de Bourses d’excellence Debiopharm à l’EPFL et création de la ‘Debiopharm academy’

Cenix BioScience and Debiopharm Group™ collaborate to identify predictive biomarkers